© 2021 MJH Life Sciences and AJMC. All rights reserved.
© 2021 MJH Life Sciences™ and Clinical Care Targeted Communications, LLC. All rights reserved.
April 02, 2021
Petros Grivas, MD, PhD, shares his thoughts on the future of maintenance therapy in locally advanced or metastatic urothelial carcinoma.
Petros Grivas, MD, PhD, discusses exciting findings and impactful data from the 2021 ASCO GU Virtual Symposium for the treatment of urothelial carcinoma.
March 24, 2021
A review of the KEYNOTE-361 study and recent findings of the post-hoc analysis looking at long-term results of pembrolizumab vs chemotherapy as first-line treatment for advanced urothelial carcinoma.
Factors influencing the sequencing of ICI (Immune checkpoint inhibitors) therapy in the second-line setting for urothelial carcinoma.